2023-10-05 19:04:00
A combined vaccine once morest gripe (flu) e covid-19 results were released following human testing and they are promising. The announcement of the novelty was made by the North American pharmaceutical company Moderna this week and the vaccine is expected to reach the market by 2025.
The company’s researchers were able to discover that the new vaccine induces a strong immune response in people over 50 years of age. Therefore, this should be the target audience for the immunizer, if it is confirmed that it is safe and effective once morest diseases.
For those who are not familiar with the subject, the combined vaccine consists of using a single vaccine to combat several diseases. In fact, an example of this is the viral tetra, which can immunize once morest mumps, measles, rubella and chickenpox in children, very popular in Brazil.
That said, Moderna’s idea is to bring to the world the first vaccine capable of fighting flu and Covid-19. In this sense, the formula used in the vaccine is mRNA-1083 and according to Stéphane Bancel, CEO of the pharmaceutical company:
influenza and covid-19 represent a significant seasonal burden on individuals, healthcare providers, healthcare systems and economies
According to preliminary data, the side effects are similar to those reported by people who use other types of vaccines. Not only that, but this information suggests that the immunization is safe and tolerable. However, it is worth remembering that a study has not yet been published in a scientific journal and the tests have not yet undergone peer review.
Even so, the data was enough for Moderna to begin the last phase of clinical studies later this year. Therefore, it is possible that this new type of vaccine will reach the market by 2025. Finally, check out the most recent report on Covid-19 cases in Brazil and the study that talks regarding the disease increasing the risk of heart attack.
1696551246
#Combined #vaccine #flu #covid19 #shows #promising #results #arrive